COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					1 Months Ended						3 Months Ended
	Jan. 01, 2024	Dec. 20, 2023	Aug. 01, 2023	Aug. 27, 2018	Jul. 31, 2022	Apr. 30, 2022	May 31, 2020	Apr. 30, 2020	Oct. 31, 2019	Jul. 31, 2019	Mar. 31, 2024	Mar. 31, 2023	Aug. 31, 2023	Apr. 04, 2022
Loss Contingencies [Line Items]
Cash consideration			$ 16,792,037
Options to acquire shares						144,191
Weighted exercise price						$ 10.71
Warrants to purchase shares						4,424
Exercise price						$ 7.32
Expiration date						Apr. 22, 2031
Payments receive			893,000
cash													$ 693,000
Cash consideration					$ 10,000,000.0
Number of shares					486,145
Cash Closing Consideration [Member]
Loss Contingencies [Line Items]
Purchase price			$ 15,250,000
Common Stock [Member]
Loss Contingencies [Line Items]
Warrants to purchase shares						12,301
Exercise price						$ 12.05
Expiration date						Aug. 10, 2030
Number of shares isssued												26,143
Precision Healing Inc [Member]
Loss Contingencies [Line Items]
Cash consideration						$ 125,966
Payments receive						$ 10,000,000.0
Precision Healing [Member]
Loss Contingencies [Line Items]
Payments receive								$ 10,000,000.0
Rochal [Member]
Loss Contingencies [Line Items]
Payment of cash							$ 500,000
Accredited Investors [Member]
Loss Contingencies [Line Items]
Issuance of shares						165,738
Nonaccredited Investors [Member]
Loss Contingencies [Line Items]
Share price														$ 30.75
Precision Healing [Member]
Loss Contingencies [Line Items]
Payment in cash						$ 600,000
Share price						$ 27.13		$ 27.13
Cost of Sales [Member]
Loss Contingencies [Line Items]
Royalty expense											$ 0	$ 520,814
Sub License Agreement [Member]
Loss Contingencies [Line Items]
License agreement and royalties description				In August 2018, the Company entered an exclusive, world-wide sublicense agreement with CGI Cellerate RX, LLC (“CGI Cellerate RX”) to distribute CellerateRX Surgical and HYCOL products into the surgical and wound care markets. Pursuant to the Sublicense Agreement, the Company pays royalties of 3-5% of annual collected net sales of CellerateRX Surgical and HYCOL. As amended in January 2021, the term of the sublicense extends through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the Sublicense Agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the expiration date, CGI Cellerate RX has the right to terminate the Sublicense Agreement upon written notice.
BIAKOS License Agreement [Member]
Loss Contingencies [Line Items]
Royalty expense											35,000	32,500
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member]
Loss Contingencies [Line Items]
Increase of royalties payable											10,000
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage										2.00%
Maximum amount of royalty												$ 130,000
BIAKOS License Agreement [Member] | Rochal Industries LLC [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage										4.00%
Maximum amount of royalty											150,000
BIAKOS Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Payment for additional royalties											$ 1,000,000
ABF License Agreement [Member]
Loss Contingencies [Line Items]
Royalty annual minimum percentage											10.00%
ABF License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage									2.00%
Maximum amount of royalty											$ 50,000
ABF License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage									4.00%
Maximum amount of royalty											75,000
Payment for additional royalties											$ 500,000
Debrider License Agreement [Member]
Loss Contingencies [Line Items]
Royalty annual minimum percentage											10.00%
Payment of cash							$ 1,000,000
Debrider License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage							2.00%
Maximum amount of royalty							$ 100,000
Debrider License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage							4.00%
Maximum amount of royalty											$ 150,000
Payment for additional royalties											$ 1,000,000
Purchase Agreement [Member]
Loss Contingencies [Line Items]
Acquisition consideration transferred					$ 7,600,000
cash					$ 1,600,000
Issuance of common stock for purchase of assets					291,686
Number of shares isssued					94,798
Purchase price					$ 7,600,000
Services Agreement [Member]
Loss Contingencies [Line Items]
Purchase agreement description			As consideration for the Petito Services, the Owner is entitled to receive: (i) a base salary of $12,000 per month during the term of the Petito Services Agreement, (ii) a royalty payment equal to three percent (3%) of the actual collections from net sales of certain products the Owner develops or codevelops that reach commercialization, (iii) a royalty payment equal to five percent (5%) for the first $50.0 million in aggregate collections from net sales of certain future products and a royalty payment of two and one-half percent (2.5%) on aggregate collections from net sales of certain future products on any amounts exceeding $50.0 million but up to $100.0 million, (iv) $500,000 in cash in the event that 510(k) clearance is issued for any future product accepted by the Company and (v) $1.0 million in cash in the event that a U.S. patent is issued for a certain product; provided that with respect to the incentive payments described in (iv) and (v) of the foregoing, the Owner shall not earn more than $2.5 million.
License Agreement [Member]
Loss Contingencies [Line Items]
Royalty expense	$ 50,000
Outstanding units percentage		10.00%
License Agreement [Member] | Royalty Agreement Terms [Member]
Loss Contingencies [Line Items]
Royalty expense	$ 100,000
License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty expense percentage		1.50%
License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty expense percentage		3.00%